EMA Opens Registry for Small and Medium Companies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Opens Registry for Small and Medium Companies


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency launched on December 20, 2010, a public registry about small and medium-sized enterprises (SME) that includes information about SME-registered companies. The goal is to facilitate interaction among these types of companies. For now the, website includes details such as company contact information, activities, and number of employees. In March 2011, according to an EMA press release, the registry will also include information about company products, including what’s in the pipeline. To be included in the registry, companies must be based in the European Economic Area and have submitted to the agency an SME declaration per the European Commission Directive 2003/361/EC.

“This initiative is in line with the overall transparency policy of the Agency,” says the EMA release. The idea is to provide more information to the pubic and, in turn, to increase support for the 20 million SMEs located throughout the European Union.

EMA also has a dedicated SME Office, which provides assistance to companies regarding the development and authorization of drug products. For example, the agency offers help with regulatory procedures, translations, fee reductions, exemptions, and deferrals, says the EMA release. There is also a helpful Question and Answer section on the new registry for SMEs needing more information.

See PharmTech related articles:
EMA Publishes New Transparency Policy (ePT)

EMA Criticized over Transparency Rules (ePT)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here